Search research articles
Contact Us
Filters
Showing results (21-30 of 36) with videos related to
Page
of 4
Sort By:
Cancer Immunology, Immunotherapy : CII
|
April 28, 2023
Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma
Qi Zhang, Jian Zhang, Haijun Zhong, et al.
Cancer Immunology, Immunotherapy : CII
|
May 7, 2024
Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer
Panpan Zhang, Zhendong Chen, Si Shi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 10, 2013
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer
Fabrice André, Thomas Bachelot, Mario Campone, et al.
Targeted Oncology
|
January 13, 2025
Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial
Hua Xu, Xin Yao, Zhisong He, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
Matthew I Milowsky, Christian Dittrich, Ignacio Durán, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2022
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
Laura Q M Chow, Fabrice Barlesi, Erin M Bertino, et al.
Therapeutic Advances in Medical Oncology
|
September 4, 2025
Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study
Yi Wang, Yifu He, Zhiqiang Wang, et al.
The Lancet. Respiratory Medicine
|
September 13, 2024
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
Yongfeng Yu, Qisen Guo, Yongchang Zhang, et al.
Experimental Hematology
|
September 16, 2025
A xeno-free red blood cell differentiation formula models sickle cell disease from somatically sourced patient iPSCs
Ashlee J Conway, Tolulope O Rosanwo, Thomas E Williamson, et al.
Stem Cell Reports
|
November 1, 2019
Morphological and Molecular Defects in Human Three-Dimensional Retinal Organoid Model of X-Linked Juvenile Retinoschisis
Kang-Chieh Huang, Mong-Lien Wang, Shih-Jen Chen, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 36) with videos related to
Sort By:
Page
of 4
Cancer Immunology, Immunotherapy : CII
|
April 28, 2023
Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma
Qi Zhang, Jian Zhang, Haijun Zhong, et al.
Cancer Immunology, Immunotherapy : CII
|
May 7, 2024
Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer
Panpan Zhang, Zhendong Chen, Si Shi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 10, 2013
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer
Fabrice André, Thomas Bachelot, Mario Campone, et al.
Targeted Oncology
|
January 13, 2025
Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial
Hua Xu, Xin Yao, Zhisong He, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
Matthew I Milowsky, Christian Dittrich, Ignacio Durán, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2022
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
Laura Q M Chow, Fabrice Barlesi, Erin M Bertino, et al.
Therapeutic Advances in Medical Oncology
|
September 4, 2025
Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study
Yi Wang, Yifu He, Zhiqiang Wang, et al.
The Lancet. Respiratory Medicine
|
September 13, 2024
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
Yongfeng Yu, Qisen Guo, Yongchang Zhang, et al.
Experimental Hematology
|
September 16, 2025
A xeno-free red blood cell differentiation formula models sickle cell disease from somatically sourced patient iPSCs
Ashlee J Conway, Tolulope O Rosanwo, Thomas E Williamson, et al.
Stem Cell Reports
|
November 1, 2019
Morphological and Molecular Defects in Human Three-Dimensional Retinal Organoid Model of X-Linked Juvenile Retinoschisis
Kang-Chieh Huang, Mong-Lien Wang, Shih-Jen Chen, et al.
Page
of 4